NASDAQ$KROS
Keros Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Keros Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
Keros Therapeutics reported a net loss of $46.0 million for the fourth quarter of 2024, an increase from the $40.2 million net loss in the same period last year. Revenue for the quarter was $3.0 million, primarily from a milestone achievement. The company's cash position was strengthened by a $200.0 million upfront payment from a license agreement with Takeda, extending its cash runway into 2029.
- Net loss for Q4 2024 was $46.0 million, compared to $40.2 million for Q4 2023, primarily due to increased R&D efforts.
- Total revenue for Q4 2024 was $3.042 million, significantly up from $0.143 million in Q4 2023, driven by a license revenue milestone.
- Research and development expenses increased to $45.6 million in Q4 2024 from $37.5 million in Q4 2023, reflecting pipeline advancement.
- Cash and cash equivalents as of December 31, 2024, were $559.9 million, bolstered by a $200.0 million upfront payment received in February 2025, extending the cash runway into 2029.
Headline financials
Revenue & EPS history
Keros · Revenue · Quarterly
$3.04M
Forward guidance
Keros Therapeutics expects its cash and cash equivalents, including the upfront payment from the Takeda Agreement, to fund its planned operating expenses and capital expenditure requirements into 2029.
Tailwinds
- Initial data from the Phase 1 clinical trial of KER-065 in healthy volunteers expected in Q1 2025, informing advancement into a Phase 2 clinical trial for neuromuscular disease.
- Continued expectation to report data from the Phase 2 TROPOS trial evaluating cibotercept (KER-012) in patients with pulmonary arterial hypertension.
- Evaluation of appropriate development strategy for cibotercept following data readout.
- Cash and cash equivalents, including the $200 million upfront payment from Takeda, are expected to fund operations into 2029.
- Advancement of promising pipeline of novel therapeutics.
Headwinds
- No specific negative forward guidance was provided in the report, but general risks associated with clinical trials and drug development are implied.
- Potential for delays in initiating, enrolling, or completing clinical trials.
- Competition from third parties developing products for similar uses.
- Risks related to obtaining, maintaining, and protecting intellectual property.
- Dependence on third parties for manufacturing, clinical trials, and preclinical studies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
+0.4%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+5.0%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+34.0%
Q3 2021
Best reaction
-15.0%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -8.5% | -17.4% | -15.4% | |
| Q4 2025 | -15.0% | -15.9% | -12.9% | |
| Q3 2025 | +3.4% | +8.0% | +38.6% | |
| Q1 2025 | +0.7% | +0.1% | -3.3% | |
| Q4 2024 | +0.6% | +5.9% | -1.4% | |
| Q3 2024 | +7.3% | +8.9% | +11.9% | |
| Q2 2024 | -8.9% | -8.0% | +7.7% | |
| Q1 2024 | -1.8% | -8.0% | -17.0% | |
| Q4 2023 | -3.6% | -1.4% | -5.4% | |
| Q3 2023 | -0.3% | -7.4% | +4.8% | |
| Q2 2023 | -10.3% | -12.9% | -12.9% | |
| Q1 2023 | -2.6% | -2.3% | +8.6% | |
| Q4 2022 | -6.4% | -3.6% | -23.4% | |
| Q3 2022 | -2.0% | -9.2% | +3.2% | |
| Q2 2022 | +14.7% | +13.5% | +10.6% | |
| Q1 2022 | -12.5% | -15.5% | -36.5% | |
| Q4 2021 | +8.7% | -3.5% | +29.9% | |
| Q3 2021 | +34.0% | +43.0% | +30.3% | |
| Q2 2021 | +5.5% | +2.6% | -3.7% | |
| Q1 2021 | -2.4% | -6.9% | -13.5% | |
| Q4 2020 | +4.4% | +6.6% | +14.0% | |
| Q3 2020 | -0.9% | +8.1% | +41.4% | |
| Q2 2020 | +7.1% | +12.8% | +23.6% | |
| Q1 2020 | -2.0% | +4.0% | +41.0% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro